$DERM News
Last published 6d ago
- 6d agoDERMFBIOJourney Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026GlobeNewswireSCOTTSDALE, Ariz., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on
- 2mo agoDERMFBIOJourney Medical Corporation to Participate in September 2026 Investor ConferencesGlobeNewswireSCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S.
- 2mo agoLGVNLGVNRIRDDERMLongeveron Appoints Nirav Jhaveri as Chief Financial OfficerGlobeNewswireMr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE)
- 3mo agoDERMFBIOJourney Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi® revenues were $8.1 million for the second quarter of 2026 Strong revenue growth and
- 3mo agoDERMFBIOJourney Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026GlobeNewswireSCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on
- 5mo agoDERMFBIOJourney Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare ConferenceGlobeNewswireSCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling
- 6mo agoDERMFBIOJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27
- 6mo agoDERMFBIOJourney Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026GlobeNewswireSCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and
- 6mo agoDERMFBIOJourney Medical Corporation Secures Contract with Third Major GPO for Emrosi™GlobeNewswireSCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on
- 7mo agoDERMFBIOJourney Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireTotal revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately
- 11mo agoDERMFBIOJourney Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyGlobeNewswireClinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or
- 12mo agoDERMFBIOJourney Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireThird quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30
- 1y agoDERMFBIOJourney Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025GlobeNewswireSCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing
- 1y agoDERMFBIOJourney Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology ConferenceGlobeNewswireFDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea
- 1y agoDERMFBIOJourney Medical Corporation to Participate in October 2025 Investor ConferencesGlobeNewswireSCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing
- 1y agoDERMFBIOJourney Medical Corporation to Participate in September 2025 Investor ConferencesGlobeNewswireSCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing
- 1y agoADVMCLNNCUAUFDERM+27Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live streamGlobeNewswireMIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth
- 1y agoDERMFBIOJourney Medical Corporation to Present at the Emerging Growth ConferenceGlobeNewswireSCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling
- 1y agoDERMJourney Medical Corporation (DERM) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoDERMFBIOJourney Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireSecond quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in
- 1y agoDERMFBIOJourney Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11GlobeNewswireSCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on
- 1y agoDERMFBIOJourney Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025GlobeNewswireSCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and
- 1y agoDERMFBIOJourney Medical Corporation Announces Expanded Payer Coverage for Emrosi™GlobeNewswirePayer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE,
- 1y agoDERMFBIOJourney Medical to Join Russell 2000® and Russell 3000® IndexesGlobeNewswireSCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on
- 1y agoDERMFBIOJourney Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology ConferenceGlobeNewswireSCOTTSDALE, Ariz., June 20, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on
- 1y agoDERMFBIOJourney Medical Corporation Announces Emrosi™ Featured on "The Balancing Act" Airing on Lifetime TVGlobeNewswireNational TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint
- 1y agoDERMFBIOJourney Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireRevenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in
- 1y agoDERMFBIOJourney Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025GlobeNewswireSCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and
- 1y agoDERMFBIOJourney Medical Corporation Appoints Ramsey Alloush as Chief Operating OfficerGlobeNewswireSCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint
- 1y agoDERMFBIOJourney Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireFDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31,
- 1y agoDERMFBIOJourney Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of RosaceaGlobeNewswireInitial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a
- 1y agoDERMFBIOJourney Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025GlobeNewswireSCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and
- 1y agoDERMFBIOJourney Medical Corporation to Participate in the 37th Annual ROTH ConferenceGlobeNewswireSCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food
- 1y agoDERMFBIOJourney Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat RosaceaGlobeNewswireDFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when
- 1y agoDERMFBIOJourney Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, FloridaGlobeNewswireSCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food
- 1y agoCKPTDERMFBIOFBIOPFortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireEmrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous
- 1y agoDERMFBIOJourney Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireU.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 Total revenues
- 2y agoDERMFBIOJourney Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaGlobeNewswireSCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food
- 2y agoDERMFBIOJourney Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology ConferenceGlobeNewswirePoster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects With its
- 2y agoDERMFBIOJourney Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceGlobeNewswireSCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and
- 2y agoDERMFBIOJourney Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) ConferenceGlobeNewswireSCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and
- 2y agoDERMFBIOJourney Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireSCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and
- 2y agoATXICKPTDERMFBIO+1Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswirePDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to treat metastatic or
- 2y agoDERMJourney Medical Corporation (DERM) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoDERMFBIOJourney Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireNew Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million
- 2y agoDERMFBIOJourney Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024GlobeNewswireSCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and
- 2y agoDERMFBIOJourney Medical Corporation Appoints Michael C. Pearce to Board of DirectorsGlobeNewswireSCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food
- 2y agoCKPTDERMFBIOFortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswireFortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug